Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budesonide/formoterol/glycopyrrolate - AstraZeneca

Next Previous
X
Search
Drug Profile

Budesonide/formoterol/glycopyrrolate - AstraZeneca

Alternative Names: BGF MDI; Breztri Aerosphere; Budesonide/formoterol fumarate/glycopyrronium; Budesonide/glycopyrrolate/formoterol; Budesonide/glycopyrronium/formoterol fumarate; Budesonide/PT 003; Formoterol/budesonide/glycopyrrolate; Formoterol/glycopyrrolate/budesonide; Formoterol/glycopyrronium bromide/budesonide; Glycopyrrolate/budesonide/formoterol; Glycopyrrolate/formoterol/budesonide; LAMA/LABA/ICS triple combination; LAMA/LABA/ICS-triple-combination-therapy; PT-003/budesonide; PT-010; Riltrava Aerosphere; Trixeo Aerosphere

Latest Information Update: 26 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pearl Therapeutics
  • Developer AstraZeneca; Pearl Therapeutics
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antispasmodics; Antiulcers; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase III Asthma

Most Recent Events

  • 11 Jun 2024 AstraZeneca completes a phase I trial for Chronic Obstructive Pulmonary Disease in Germany (Inhalation) (NCT06297668)
  • 17 May 2024 Adverse events and pharmacokinetics data from a phase I trial in Chronic obstructive pulmonary disease presented at the 120th International Conference of the American Thoracic Society (ATS-2024)
  • 29 Apr 2024 AstraZeneca initiates a phase I trial for Chronic Obstructive Pulmonary Disease in Germany (Inhalation) (NCT06297668)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top